TickerFacts.

Tevogen Inc. (TVGN): Capital Expenditures

Annual figures by period end, from SEC filings.

$64.4K
Year ended 2025-12-31
$133.0K2023-12-31: $133.0K2025-12-31: $64.4K$64.4K
2023-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$64.4Kn/a2026-03-31, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31$133.0Kn/a2025-04-02, From 2023-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Tevogen Inc. (TVGN)2025-12-31$64.4Kn/a
BioCardia, Inc. (BCDA)2025-12-31$7.0K+16.7%
AIM ImmunoTech Inc. (AIM)2024-12-31$18.0Kn/a
Exozymes Inc. (EXOZ)2025-12-31$169.9K-57.1%
Silexion Therapeutics Corp (SLXN)2025-12-31$9.0K-59.1%
VivoSim Labs, Inc. (VIVS)2026-03-31$0-100.0%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$24.0K+100.0%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$23.0Kn/a
Entera Bio Ltd. (ENTX)2025-12-31$107.0Kn/m

Compare TVGN, BCDA, AIM, EXOZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗